Nuvation Bio, Inc. (NUVB)
| Market Cap | 2.06B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -49.21M |
| Shares Out | 216.76M |
| EPS (ttm) | -0.40 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 337,343 |
| Open | 9.55 |
| Previous Close | 9.47 |
| Day's Range | 9.24 - 9.57 |
| 52-Week Range | 7.66 - 15.23 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | 18.20 (+96.8%) |
| Est. Earnings Date | Oct 28, 2021 |
About NUVB
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting CDK2, CDK4, and CDK6. It is also developing NUV-868, a selective inhibitor of the BET family of epigenetic transcriptional regulators; NUV-569, a differentiated selective inhibitor of the Wee1 kinase; NUV-1182, an adenosine receptor inhibitor; and DDC platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PAR...
Financial Performance
Financial StatementsNews
Nuvation Bio Reports Second Quarter 2021 Financial Results and Provides Business Update
NEW YORK, Aug. 12, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeut...
Nuvation Bio Appoints David C. Hanley, Ph.D.
NEW YORK, June 1, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeuti...
Nuvation Bio to Participate in the Jefferies Virtual Healthcare Conference
NEW YORK, May 26, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeuti...
Nuvation Bio Reports First Quarter 2021 Financial Results and Provides Business Update
NEW YORK, May 17, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeuti...
Panacea Acquisition Corp. II Announces Pricing of $150,000,000 Initial Public Offering
SAN FRANCISCO, CA, April 06, 2021 (GLOBE NEWSWIRE) -- Panacea Acquisition Corp. II (the “Company”), a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition,...
Panacea Announces Effectiveness of Registration Statement for Proposed Business Combination with Nuvation Bio
SAN FRANCISCO--(BUSINESS WIRE)--Panacea Acquisition Corp., a Delaware corporation (the “Company”) (NYSE: PANA.U, PANA, PANA WS), announced today that its registration statement on Form S-4 (File No. 333...
4 SPAC Mergers: What The KBLM, ACAM, PANA And SMMC Deals Mean For Investors
Last week saw continued momentum in special purpose acquisition company (SPAC) mergers, as KBL Merger (NASDAQ: KBLM), Acamar Partners Acquisition Corp. (NASDAQ: ACAM), Panacea Acquisition Corp. (NYSE: P...